Article info

Download PDFPDF

Original article
Results of a phase IIa study of VX-809, an investigational CFTR corrector compound, in subjects with cystic fibrosis homozygous for the F508del-CFTR mutation

Authors

  1. Correspondence to Dr JP Clancy, Cincinnati Children's Hospital Medical Center, 3333 Burnet Avenue, Cincinnati, OH 45229, USA; john.clancy{at}cchmc.org
View Full Text

Citation

Clancy JP, Rowe SM, Accurso FJ, et al
Results of a phase IIa study of VX-809, an investigational CFTR corrector compound, in subjects with cystic fibrosis homozygous for the F508del-CFTR mutation

Publication history

  • Received April 29, 2011
  • Accepted July 1, 2011
  • First published August 8, 2011.
Online issue publication 
December 14, 2011

Article Versions

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.